Amendment for BWI-PT-Barrier (pOTA)

Request for Project Proposal (RPP)
Solicitation Number: HT942726RE020
Amendment No. 0002
Prototype development for Battlefield
Wound Infection Prevention and
Treatment (BWI P&T) Barrier
Combination
Issued by the:
Defense Health Agency Contracting Activity (DHACA)

808 SCHREIDER ST

FORT DETRICK MD 21702

for the:
Defense Health Agency (DHA)
Portfolio Acquisition Executive Medical Products (PAE MP) Warfighter Protection and Acute Care
Project Management Office

(WPAC PMO)

Issue Date: Wednesday, 23 Sep 2026
Amendment 0002: Monday, 19 Oct 2026
Proposal Due Date: Friday, 06 November 2026

RPP No. HT942726RE020

Prototype development for Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier

1.1
1.2
1.3
1.4
2.1
2.2
2.3
2.4
2.5
2.6
3.1
3.2
3.3
3.4
3.5
4.1
4.2
4.3

RPP No. HT942726RE020

Prototype development for Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier

1. Executive Summary

1.1 Request for Project Proposal (RPP)

This RPP is being issued by the Defense Health Agency Contracting Activity (DHACA), in support of the Defense Health Agency’s Portfolio Acquisition Executive (PAE) Medical Products (MP) Warfighter Protection (WPAC) & Acute Care Program Management Office (PMO) Care located in Frederick, Maryland at Fort Detrick. The Warfighter Protection and Acute Care Project Management Office (WPAC PMO) has a requirement for the development of a Barrier Combination product. The Barrier Combination product is defined as being composed of both a physical barrier to protect a wound and an antibacterial and/or antifungal activity released from the barrier to prevent the spread of organisms and avoid systemic infections.
This RPP will result in one award to develop the Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination (BC) prototype product. The final product MUST be a combination wound treatment that includes a barrier component that is either infused or impregnated with antimicrobial and/or antifungal properties and have U.S. Food Drug Administration (FDA) approval (or clearance). The award, as a result of this RPP, will be awarded under the authority of prototype Other Transaction Authority (pOTA) 10 U.S.C. 4022.

1.2 Background

The BWI P&T program is focused on identifying potential medical products for maturation that can prevent and treat infections in wounds sustained in combat. Current battlefield wound management care is governed based on the possibility of timely